RNA interference as an anticancer therapy: A patent perspective

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 4, 2009, Pages 475-491

  Dykxhoorn, Derek M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Drug discovery; Genetic therapy; RNA interference

Indexed keywords

ADENOVIRUS VECTOR; ANGIOPOIETIN; ATELOCOLLAGEN; CHITOSAN; CISPLATIN; IMATINIB; LENTIVIRUS VECTOR; LIPOSOME; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; RETROVIRUS VECTOR; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; VASCULOTROPIN;

ADENOVIRUS; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; COLORECTAL CANCER; DNA VECTOR; DRUG DELIVERY SYSTEM; GENE DELIVERY SYSTEM; GENE SILENCING; GENETIC STABILITY; HUMAN; LENTIVIRINAE; LUNG SQUAMOUS CELL CARCINOMA; MELANOMA; NASOPHARYNX CANCER; NONHUMAN; ONCOGENE; PATENT; RETINA MACULA AGE RELATED DEGENERATION; RETINOBLASTOMA; RETROVIRUS; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER;

ANIMALS; GENE SILENCING; GENE TARGETING; GENE THERAPY; HUMANS; NEOPLASMS; PATENTS AS TOPIC; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 67649624970     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770902838008     Document Type: Review

References (197)

1. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-811 (Pubitemid 28099681)
2. Farazi TA, Juranek SA, Tuschl T. The growing catalog of small RNAs and their association with distinct Argonaute/Piwi family members. Development 2008;135:1201-1214 (Pubitemid 351622465)
3. Matranga C, Zamore PD. Small silencing RNAs. Curr Biol 2007;17:R789-93 (Pubitemid 47380389)
4. Hannon GJ, Rivas FV, Murchison EP, Steitz JA. The expanding universe of noncoding RNAs. Cold Spring Harb Symp Quant Biol 2006;71:551-564
5. Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007;129:1401-1414 (Pubitemid 46970709)
6. Kim VN, Nam JW. Genomics of microRNA. Trends Genet 2006;22:165-173 (Pubitemid 43290020)
7. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. Embo J 2004;23:4051-4060 (Pubitemid 39472426)
8. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003;425:415-419 (Pubitemid 37187272)
9. Denli AM, Tops BB, Plasterk RH, et al. Processing of primary microRNAs by the Microprocessor complex. Nature 2004;432:231-235 (Pubitemid 39545854)
10. Landthaler M, Yalcin A, Tuschl T. The human DiGeorge syndrome critical region gene 8 and Its D. melanogaster homolog are required for miRNA biogenesis. Curr Biol 2004;14:2162-2167 (Pubitemid 39623200)
11. Lund E, Guttinger S, Calado A, et al. Nuclear export of microRNA precursors. Science 2004;303:95-98 (Pubitemid 38055779)
12. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001;409:363-366 (Pubitemid 32151243)
13. Chendrimada TP, Gregory RI, Kumaraswamy E, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005;436:740-744 (Pubitemid 41117280)
14. Tang G. siRNA and miRNA: an insight into RISCs. Trends Biochem Sci 2005;30:106-114 (Pubitemid 40187303)
15. Sen GL, Blau HM. Argonaute 2/RISC resides in sites of mammalian mRNA decay known as cytoplasmic bodies. Nat Cell Biol 2005;7:633-636 (Pubitemid 40796987)
16. Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev 2004;18:504-511 (Pubitemid 38372808)
17. Doench JG, Petersen CP, Sharp PA. siRNAs can function as miRNAs. Genes Dev 2003;17:438-442
18. Bagga S, Bracht J, Hunter S, et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 2005;122:553-563 (Pubitemid 41191154)
19. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005;433:769-773 (Pubitemid 40292988)
20. Kutter C, Svoboda P. miRNA, siRNA, piRNA: knowns of the unknown. RNA Biol 2008;5:181-188
21. Lewis BP, Shih IH, Jones-Rhoades MW, et al. Prediction of mammalian microRNA targets. Cell 2003;115:787-798 (Pubitemid 38058492)
22. Farh KK, Grimson A, Jan C, et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 2005;310:1817-1821 (Pubitemid 41814382)
23. Dykxhoorn DM, Chowdhury D, Lieberman J. RNA interference and cancer: endogenous pathways and therapeutic approaches. Adv Exp Med Biol 2008;615:299-329
24. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-833 (Pubitemid 40839734)
25. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005;102:13944-13949 (Pubitemid 41377683)
26. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004;101:2999-3004 (Pubitemid 38327724)
27. Okamura K, Chung WJ, Lai EC. The long and short of inverted repeat genes in animals: microRNAs, mirtrons and hairpin RNAs. Cell Cycle 2008;7:2840-2845
28. Okamura K, Balla S, Martin R, et al. Two distinct mechanisms generate endogenous siRNAs from bidirectional transcription in Drosophila melanogaster. Nat Struct Mol Biol 2008;15:998 (Pubitemid 351799142)
29. Okamura K, Chung WJ, Ruby JG, et al. The Drosophila hairpin RNA pathway generates endogenous short interfering RNAs. Nature 2008;453:803-806 (Pubitemid 351793790)
30. Golden DE, Gerbasi VR, Sontheimer EJ. An inside job for siRNAs. Mol Cell 2008;31:309-312
31. Okamura K, Lai EC. Endogenous small interfering RNAs in animals. Nat Rev Mol Cell Biol 2008;9:673-678
32. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001;15:188-200 (Pubitemid 32107664)
33. Dykxhoorn DM, Novina CD, Sharp PA. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003;4:457-467 (Pubitemid 36648591)
34. Amarzguioui M, Lundberg P, Cantin E, et al. Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. Nat Protoc 2006;1:508-517
35. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-498 (Pubitemid 32494397)
36. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-799 (Pubitemid 39070849)
37. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70 (Pubitemid 30046295)
38. Croce CM. Oncogenes and cancer. N Engl J Med 2008;358:502-511 (Pubitemid 351185806)
39. Sherr CJ. Principles of tumor suppression. Cell 2004;116:235-246 (Pubitemid 38167315)
40. Hubbard SR, Miller WT. Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol 2007;19:117-123 (Pubitemid 46386407)
41. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000;19:5548-5557
42. Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 2006;24:21-44 (Pubitemid 43108774)
43. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-365 (Pubitemid 32467045)
44. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002;7(Suppl 4):31-39
45. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002;109(Suppl):S121-31
46. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-3310
47. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27:5497-5510
48. Steelman LS, Abrams SL, Whelan J, et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008;22:686-707
49. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-354 (Pubitemid 40637826)
50. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007;26:3279-3290 (Pubitemid 46763021)
51. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003;3:459-465 (Pubitemid 37328850)
52. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002;2:243-247 (Pubitemid 41043979)
53. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934
54. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954 (Pubitemid 34716871)
55. McSwiggen J, Beigelman L. RNA interference meditaed inhibition of Myc and Myb gene expression or expression of genes involved in the myc and myb pathways using short interfering nucleic acid (siNA). WO2003US05326; 2003
56. Fujita DJ, Bjorge JD. Methods and reagents for inhibiting cell proliferation US20060453099; 2006
57. Khvorova A, Reynolds A, Leake D, et al. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC). US20070818547 2005
58. Frohling S, Dohner H. Chromosomal abnormalities in cancer. N Engl J Med 2008;359:722-734
59. Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene 2003;22:9007-9021 (Pubitemid 38121701)
60. Macauley VM, Sohail M. Molecular targeting of the IGF-1 receptor. US20040996951; 2005
61. Khvorova A, Reynolds A, Leake D, et al. siRNA targeting insulin-like growth factor 1 receptor (IGF-1R). US20070732457; 2007
62. Evers BM, Rychahou P. SiRNA targeting PI3K signal transduction pathway and siRNA-based therapy. US20050085962; 2005
63. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-410 (Pubitemid 37328844)
64. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-286
65. Quay SC, McSwiggen J, Vaish NK, Ahmadian M. Nucleic Acid compounds for inhibiting VEGF gene expression and uses thereof. US2008003965020080228; 2008
66. Vargeese C, Jadhav V, Morrissey D. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA). US2005029939120051209; 2006
67. Kossen K, Jadhav V, Mcswiggen J, et al. RNA interference mediated inhibition of vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA). CA2004253708520040916; 2005
68. Liu Y, Lu PY, Woodle MC, Xie FY. Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases. US2007082442620070629; 2008
69. Fougerollles AD, Frank-Kamenetsky M, Manoharan M, et al. IRNA agents targeting VEGF. US2006034008020060125; 2006
70. Trask DK, Bock J. Methods of inhibiting VEGF-C. US2006058558720061024; 2007
71. Shen J, Samul R, Silva RL, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006;13:225-234 (Pubitemid 43148645)
72. Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003;9:210-216 (Pubitemid 38097589)
73. Lu PY, Xie FY, Woodle MC. Modulation of angiogenesis with siRNA inhibitors for novel therapeutics. Trends Mol Med 2005;11:104-113 (Pubitemid 40348987)
74. Campochiaro PA. Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. Gene Ther 2006;13:559-562
75. Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 2008;27:85-94
76. Shinomiya N, Woude GFV. C-Met Sirna adenovirus vectors inhibit cancer cell growth, invasion and tumorigenicity. US20050599327; 2007
77. Khvorova A, Reynolds A, Leake D, et al. siRNA Targeting proto-oncogene MET. US20070980263; 2008
78. Reich SJ, Tolentino MJ. Compositions and methods for siRNA inhibition of angiopoietin 1and 2 and their receptor Tie2. US20040827759; 2004
79. Thurston G. Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 2003;314:61-68 (Pubitemid 37409913)
80. Kraus MH, Pierce JH, Fleming TP, et al. Mechanisms by which genes encoding growth factors and growth factor receptors contribute to malignant transformation. Ann NY Acad Sci 1988;551:320-35; discussion 36 (Pubitemid 19172152)
81. Khvorova A, Reynolds A, Leake D, et al. siRNA targeting platelet-derived growth factor receptor beta polypeptide (PDGFR). US20070731890; 2008
82. McSwiggen J, Beigelman L, Chowrira BM. RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA). US20040923270; 2005
83. Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 2003;63:1515-1519 (Pubitemid 36373637)
84. Stege A, Priebsch A, Nieth C, Lage H. Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference. Cancer Gene Ther 2004;11:699-706 (Pubitemid 39488467)
85. Nieth C, Priebsch A, Stege A, Lage H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett 2003;545:144-150
86. Duan Z, Brakora KA, Seiden MV. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther 2004;3:833-838 (Pubitemid 39193765)
87. McSwiggen J, Beigelman L, Thompson J. RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA). US20040918969; 2005
88. Zhang X, Kon T, Wang H, et al. Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res 2004;64:8139-8142 (Pubitemid 39491746)
89. Akinc A, De Fougerolles A, Vornlocher HP, et al. RNAI modulation of HIF-1 and therapeutic uses thereof. EP20060785707; 2008
90. Usman N, McSwiggen J. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA). WO2004US27294; 2005
91. Deweese TL, Collins SJ, Nelson WG. Engineered rnai adenovirus silencing expression (erase) of dna repair proteins. US20050534010; 2005
92. Chang IY, Kim MH, Kim HB, et al. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophys Res Commun 2005;327:225-233 (Pubitemid 40051375)
93. Chen J, Wall NR, Kocher K, et al. Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin. J Clin Invest 2004;113:1784-1791 (Pubitemid 39071670)
94. McSwiggen J, Beigelman L, Chowrira BM. RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA). US20040923522; 2005
95. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-681 (Pubitemid 40825512)
96. Khvorova A, Reynolds A, Leake D, et al. Functional and hyperfunctional siRNA directed against Bcl-2. US20070974878; 2008
97. McSwiggen J, Beigelman L. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA). US20040923516; 2005
98. Sonoke S, Ueda T, Fujiwara K, et al. Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes. Cancer Res 2008;68:8843-8851
99. Sun H, Ghosh P, Kim Y. Methods of treating cancer by interfering with IGF-1 receptor signaling. WO2008US03393; 2008
100. McSwiggen J, Beigelman L, Chowrira B. RNA interference mediated inhibition of type 1 insulin-like receptor (IGF-1R) gene expression using short interfering nucleic acid (siNA). WO2003US05044; 2003
101. Aza-Blanc P, Cooper CL, Wagner K, et al. Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol Cell 2003;12:627-637 (Pubitemid 37222485)
102. Dykxhoorn DM, Lieberman J. The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu Rev Med 2005;56:401-423 (Pubitemid 40299790)
103. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003;424:797-801 (Pubitemid 37021711)
104. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002;2:331-341 (Pubitemid 37328946)
105. Berns K, Hijmans EM, Mullenders J, et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004;428:431-437 (Pubitemid 38419689)
106. Jadhav V, Carrol JM, Terpstra AJ. RNA interference mediated inhibition of histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA). AU20060261653; 2008
107. Vornlocher HP, Tan P, Constein R. RNAi modulation of TGF-beta and therapeutic uses thereof. EP20070753200; 2008
108. Guerciolini R, Robin H, McSwiggen J. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA). US20050054047; 2005
109. Westbrook TF, Martin ES, Schlabach MR, et al. A genetic screen for candidate tumor suppressors identifies REST. Cell 2005;121:837-848 (Pubitemid 40806416)
110. Kolfschoten IG, van Leeuwen B, Berns K, et al. A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell 2005;121:849-858 (Pubitemid 40806417)
111. Ngo VN, Davis RE, Lamy L, et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006;441:106-110 (Pubitemid 43827960)
112. Silva JM, Marran K, Parker JS, et al. Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 2008;319:617-620 (Pubitemid 351197063)
113. Schlabach MR, Luo J, Solimini NL, et al. Cancer proliferation gene discovery through functional genomics. Science 2008;319:620-624 (Pubitemid 351197064)
114. Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther 2006;13:541-552
115. Dykxhoorn DM, Lieberman J. Knocking down disease with siRNAs. Cell 2006;126:231-235 (Pubitemid 44092975)
116. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005;11:50-55 (Pubitemid 40215837)
117. Palliser D, Chowdhury D, Wang QY, et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 2006;439:89-94 (Pubitemid 43053634)
118. Li BJ, Tang Q, Cheng D, et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med 2005;11:944-951 (Pubitemid 41294439)
119. Behlke MA. Progress towards in vivo use of siRNAs. Mol Ther 2006;13:644-670
120. Tousignant JD, Gates AL, Ingram LA, et al. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. Hum Gene Ther 2000;11:2493-2513
121. Dass CR. Cytotoxicity issues pertinent to lipoplex-mediated gene therapy in-vivo. J Pharm Pharmacol 2002;54:593-601 (Pubitemid 34456018)
122. Chien PY, Wang J, Carbonaro D, et al. Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther 2005;12:321-328 (Pubitemid 40315192)
123. Ahmad I, Zhang ZY, Zhang JA, et al. Lipid compositions and use thereof. CA20052559352; 2005
124. Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005;23:1002-1007 (Pubitemid 41114035)
125. McSwiggen J, Morrissey D, Guerciolini R, et al. RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA). WO2006US62252; 2007
126. Czech B, Malone CD, Zhou R, et al. An endogenous small interfering RNA pathway in Drosophila. Nature 2008;453:798-802 (Pubitemid 351793787)
127. Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441:111-114 (Pubitemid 43827961)
128. Urban-Klein B, Werth S, Abuharbeid S, et al. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005;12:461-466 (Pubitemid 40394299)
129. Leong KW, Mao HQ, Truong-Le VL, et al. DNA-polycation nanospheres as non-viral gene delivery vehicles. J Control Release 1998;53:183-193 (Pubitemid 28218701)
130. Gary DJ, Puri N, Won YY. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release 2007;121:64-73 (Pubitemid 47126065)
131. Schiffelers RM, Ansari A, Xu J, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004;32:e149
132. Pun SH, Bellocq NC, Liu A, et al. Cyclodextrin-modified polyethylenimine polymers for gene delivery. Bioconjug Chem 2004;15:831-840 (Pubitemid 38981958)
133. Pun SH, Tack F, Bellocq NC, et al. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol Ther 2004;3:641-650 (Pubitemid 41351103)
134. Davis ME, Pun SH, Bellocq NC, et al. Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers. Curr Med Chem 2004;11:179-197 (Pubitemid 38128844)
135. Borchard G, Junginger HE. Modern drug delivery applications of chitosan. Adv Drug Deliv Rev 2001;52:103 (Pubitemid 33079165)
136. Howard KA, Rahbek UL, Liu X, et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 2006;14:476-484 (Pubitemid 44296092)
137. Howard KA, Paludan SR, Behlke MA, et al. Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther 2009;17:162-168
138. Hanai K, Takeshita F, Honma K, et al. Atelocollagen-mediated systemic DDS for nucleic acid medicines. Ann NY Acad Sci 2006;1082:9-17 (Pubitemid 44955443)
139. Takeshita F, Minakuchi Y, Nagahara S, et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 2005;102:12177-12182 (Pubitemid 41291148)
140. Minakuchi Y, Takeshita F, Kosaka N, et al. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 2004;32:e109
141. Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005;23:709-717 (Pubitemid 41716361)
142. Peer D, Zhu P, Carman CV, et al. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci USA 2007;104:4095-4100 (Pubitemid 47181584)
143. Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007;448:39-43 (Pubitemid 47037001)
144. Kumar P, Ban HS, Kim SS, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008;134:577-586
145. Lieberman J, Song E. Method of Delivering Rna Interference and Uses Thereof. US20050659386; 2008
146. Peer D, Shimaoka M, Lieberman J. Targeted delivery to leukocytes using protein carriers. WO2007US09975; 2007
147. Peer D, Park EJ, Morishita Y, et al. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008;319:627-630 (Pubitemid 351197066)
148. Thompson J, McSwiggen J, Beigelman L. RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA). WO2003US03662; 2003
149. Shankar P, Lee SK, Swamy M, et al. Targeted delivery of siRNA. WO2008US52054; 2008
150. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432:173-178 (Pubitemid 39545841)
151. Narasimhaswamy M, Shankar P, Kumar P. Method for delivery across the blood brain barrier. WO2007US12152; 2008
152. Lengyel E, Kossiakoff A, Piccirilli J. Receptor-mediated delivery: compositions and methods. WO2008014404; 2008
153. Wright DG, Murphy JR, Zhang Y. Cellular delivery of reagens that inhibit gene expression utilizing the anthrax toxin protective antigen (PA). WO2006091233; 2006
154. McNamara JO 2nd, Andrechek ER, Wang Y, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006;24:1005-1015
155. Sullenger BA. Delivery method. WO2007US12927; 2007
156. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007;8:173-184 (Pubitemid 46272217)
157. Grimm D, Kay MA. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest 2007;117:3633-3641
158. Grimm D, Kay MA. RNAi and gene therapy: a mutual attraction. Hematology Am Soc Hematol Educ Prog 2007;2007:473-481
159. Schaffer DV, Koerber JT, Lim KI. Molecular engineering of viral gene delivery vehicles. Annu Rev Biomed Eng 2008;10:169-194
160. Benihoud K, Yeh P, Perricaudet M. Adenovirus vectors for gene delivery. Curr Opin Biotechnol 1999;10:440-447 (Pubitemid 29457268)
161. Lee YJ, Imsumran A, Park MY, et al. Adenovirus expressing shRNA to IGF-1R enhances the chemosensitivity of lung cancer cell lines by blocking IGF-1 pathway. Lung Cancer 2007;55:279-286 (Pubitemid 46343577)
162. Shinomiya N, Gao CF, Xie Q, et al. RNA interference reveals that ligandin-dependent met activity is required for tumor cell signaling and survival. Cancer Res 2004;64:7962-7970 (Pubitemid 39446930)
163. Yoo JY, Kim JH, Kwon YG, et al. VEGF-specific short hairpin RNAexpressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther 2007;15:295-302 (Pubitemid 46111879)
164. Zheng JN, Pei DS, Sun FH, et al. Inhibition of renal cancer cell growth by oncolytic adenovirus armed short hairpin RNA targeting hTERT gene. Cancer Biol Ther 2009;8
165. Zheng JN, Pei DS, Mao LJ, et al. Inhibition of renal cancer cell growth in vitro and in vivo with oncolytic adenovirus armed short hairpin RNA targeting Ki-67 encoding mRNA. Cancer Gene Ther 2009;16:20-32
166. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008;21:583-593
167. Hildinger M, Auricchio A. Decreasing gene expression in a mammalian subject in vivo via AAV-mediated RNAi expression cassette transfer. US2005019927; 2005:80-87
168. Tomar RS, Matta H, Chaudhary PM. Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene 2003;22:5712-5715 (Pubitemid 37102709)
169. Noguchi P. Risks and benefits of gene therapy. N Engl J Med 2003;348:193-194 (Pubitemid 36077913)
170. Sumimoto H, Yamagata S, Shimizu A, et al. Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference. Gene Ther 2005;12:95-100 (Pubitemid 40090049)
171. Sumimoto H, Hirata K, Yamagata S, et al. Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi. Int J Cancer 2006;118:472-476 (Pubitemid 41779089)
172. Sumimoto H, Miyagishi M, Miyoshi H, et al. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 2004;23:6031-6039 (Pubitemid 39178855)
173. Pichler A, Zelcer N, Prior JL, et al. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res 2005;11:4487-4494
174. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006;441:537-541 (Pubitemid 44050158)
175. An DS, Qin FX, Auyeung VC, et al. Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol Ther 2006;14:494-504
176. An DS, Donahue RE, Kamata M, et al. Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci USA 2007;104:13110-13115
177. Giering JC, Grimm D, Storm TA, Kay MA. Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 2008;16:1630-1636
178. Dickins R, Hannon GJ, Lowe SW. Methods for producing miRNAs. EP1896587; 2008
179. Dykxhoorn DM, Schlehuber LD, London IM, Lieberman J. Determinants of specific RNA interference-mediated silencing of human beta-globin alleles differing by a single nucleotide polymorphism. Proc Natl Acad Sci USA 2006;103:5953-5958
180. Jackson AL, Bartz SR, Schelter J, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003;21:635-637 (Pubitemid 36638089)
181. Lin X, Ruan X, Anderson MG, et al. siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res
182. Anderson EM, Birmingham A, Baskerville S, et al. Experimental validation of the importance of seed complement frequency to siRNA specificity. RNA 2008;14:853-861 (Pubitemid 351574907)
183. Jackson AL, Burchard J, Schelter J, et al. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 2006;12:1179-1187
184. Sioud M. RNA interference and innate immunity. Adv Drug Deliv Rev 2007;59:153-163 (Pubitemid 46783844)
185. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004;303:1526-1529 (Pubitemid 38314424)
186. Judge AD, Sood V, Shaw JR, et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005;23:457-462 (Pubitemid 41724921)
187. Sioud M. Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2′-hydroxyl uridines in immune responses. Eur J Immunol 2006;36:1222-1230
188. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511 (Pubitemid 38931765)
189. Sioud M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 2005;348:1079-1090 (Pubitemid 40602367)
190. Robbins M, Judge A, Ambegia E, et al. Misinterpreting the therapeutic effects of siRNA caused by immune stimulation. Hum Gene Ther 2008
191. Akinc A, Zumbuehl A, Goldberg M, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008;26:561-569 (Pubitemid 351668042)
192. Manoharan M, Rajeev KG, Akinc A, et al. Lipid containing formulations. WO2007US80331; 2008
193. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302:415-419 (Pubitemid 37296260)
194. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348:255-256 (Pubitemid 36077924)
195. Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008;452:591-597
196. Schmidt C. Negotiating the RNAi patent thicket. Nat Biotechnol 2007;25:273-275 (Pubitemid 46398756)
197. Haussecker D. The business of RNAi therapeutics. Hum Gene Ther 2008;19:451-462 (Pubitemid 351748790)